Review Article
Hypertension in Chronic Kidney Disease: An Update on Diagnosis and Management
Abstract
Hypertension (HTN) and chronic kidney disease (CKD) are pathophysiologic states that are intimately related, such that long-term HTN can lead to poor kidney function, and renal function decline can lead to worsening blood pressure (BP) control. HTN in CKD is caused by an interplay of factors, including salt and water retention, with extracellular volume expansion, sympathetic nervous system overactivity, renin-angiotensin-aldosterone system activation, and endothelial dysfunction. BP variability in the CKD population is significant, however, and thus requires close monitoring for appropriate management. With accumulating evidence, the diagnosis as well as management of HTN in CKD has been evolving in the last decade. In this comprehensive review based on current evidence and recommendations, we summarize the basics of pathophysiology, BP variability, diagnosis, and management of HTN in CKD with an emphasis on special populations with CKD.Posted in: Nephrology and Urology22 Chronic Kidney Disease3
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Harlos J, Heidland A. Hypertension as cause and consequence of renal disease in the 19th century. Am J Nephrol 1994;14:436–442.
2. Mahomed FA. The etiology of Bright’s disease and the prealbuminuric stage. Med Chir Trans 1874;57:197.
3. Saran R, Robinson B, Abbott KC, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2020;75:A6–A7.
4. Mailloux LU. Hypertension in the dialysis patient. Am J Kidney Dis 1999;34: 359–361.
5. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010;55:441–451.
6. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011;57:1076–1080.
7. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013;8:1583–1590.
8. Rao MV, Qiu Y, Wang C, et al. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008;51:S30–S37.
9. Zarif L, Covic A, Iyengar S, et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000; 15:1801–1807.
10. Zucchelli P, Zuccala A. Can we accurately diagnose nephrosclerosis? Nephrol Dial Transplant 1995;10(Supp 6):2–5.
11. Mennuni S, Rubattu S, Pierelli G, et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens 2014;28:74–79.
12. Wadei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol 2012 Oct;8(10):602–609.
13. Koomans HA, Roos JC, Boer P, et al. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982;4:190–197.
14. Koomans HA, Roos JC, Dorhout Mees EJ, et al. Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. Hypertension 1985;7:714–721.
15. Guyton AC, Manning RD, Norman RA, et al. Current concepts and perspectives of renal volume regulation concerning hypertension. J Hypertens Suppl 1986;4: S49–S56.
16. Schalekamp MA, Schalekamp-Kuyken MP, de Moor-Fruytier M, et al. Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 1973;45:417–428.
17. Feng W, Dell’Italia LJ, Sanders PW. Novel paradigms of salt and hypertension. J Am Soc Nephrol 2017;28:1362–1369.
18. Ito Y, Noda H, Isaka M, et al. Norepinephrine responsiveness in patients with borderline hypertension under three different sodium balances. Clin Exp Hypertens A 1989;11(suppl 1):363–370.
19. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to hypertension and kidney disease pathobiology. Pharmacol Rev 2007;59:251–287.
20. Boer P, Dorhout Mees EJ, Roos JC, et al. Renin and body fluid volumes in chronic renal disease. Relations between arterial pressure, plasma renin activity, blood volume, and extracellular volume in chronic renal disease, as compared with essential hypertension. Acta Med Scand 1981;210:207–212.
21. Griffin KA. Hypertensive kidney injury and the progression of chronic kidney disease. Hypertension 2017;70:687–694.
22. Bertocchio JP, Jaisser F. Aldosterone and kidney diseases: an emergent paradigm with important clinical implications. Nephrol Ther 2010;7:139–147.
23. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286–290.
24. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912–1918.
25. DiBona GF. Sympathetic nervous system and hypertension. Hypertension 2013;61:556–560.
26. Zbroch E, Małyszko J, Zórawski MJ, et al. Kidney and hypertension: is there a place for renalase? Pol Arch Med Wewn 2012;122:174–179.
27. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004;24:354–365.
28. Clavell AL, Stingo AJ, Margulies KB, et al. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol 1995; 268(3 Pt 2):F455–F460.
29. Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989;1(8645):991–992.
30. Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrol Dial Transplant 2018;33:1690–1698.
31. Simeoni M, Perna AF, Fuiano G. Secondary hyperparathyroidism and hypertension: an intriguing couple. Journal of clinical medicine 2020 Mar; 9(3):629.
32. Phan O, Burnier M, Wuerzner G. Hypertension in chronic kidney disease– role of arterial calcification and impact on treatment. European Cardiology Review 2014 Dec;9(2):115.
33. Meyrier A. Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant 2015 Nov;30(11):1833–41.
34. Hill GS, Heudes D, Jacquot C, et al. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int. 2006 Mar;69(5):823–31.
35. Whelton PK, Carey RM, Aronow WS, et al. 2017. ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018 May 15;71(19):e127–e248.
36. Drawz PE, Ix JH. BP measurement in clinical practice: time to SPRINT to guideline-recommended protocols. J Am Soc Nephrol 2018;29:383–388.
37. Brothwell S, Dutton M, Ferro C, et al. Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU. BMC Nephrol 2013;14:218.
38. Thomas G, Drawz PE. BP measurement techniques: what they mean for patients with kidney disease. Clin J Am Soc Nephrol 2018;13:1124–1131.
39. Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021;99:S1–S87.
40. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–3104.
41. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008;52:10–29.
42. Georgianos PI, Agarwal R. Hypertension in chronic kidney disease (CKD): diagnosis, classification, and therapeutic targets. Am J Hypertens 2021;34: 318–326.
43. Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol 2016;11:642–652.
44. Parati G, Agabiti-Rosei E, Bakris GL, et al. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) study: a randomised controlled trial protocol. BMJ Open 2018; 8:e021038.
45. Mojón A, Ayala DE, Piñeiro L, et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 2013;30:145–158.
46. Redon J, Plancha E, Swift PA, et al. Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. J Hypertens 2010;28:602–607.
47. Agarwal R, Kariyanna SS, Light RP. Prognostic value of circadian blood pressure variation in chronic kidney disease. Am J Nephrol 2009;30:547–553.
48. Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007;50:908–917.
49. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2020;41:4565–4576.
50. Parati G, Ochoa JE, Lombardi C, et al. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013;10:143–155.
51. Chang TI, Tabada GH, Yang J, et al. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J Hypertens 2016;34:244–252.
52. Tanner RM, Shimbo D, Dreisbach AW, et al. Association between 24-hour blood pressure variability and chronic kidney disease: a cross-sectional analysis of African Americans participating in the Jackson Heart Study. BMC Nephrol 2015;16:84.
53. Ku E, Lee BJ, Wei J, et al. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis 2019;74:120–131.
54. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019;79:365–379.
55. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75.
56. Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27:1629–1651.
57. Huang W. Evening-versus morning dosing drug therapy for chronic kidney disease patients with hypertension: a systematic review. Kidney Blood Press Res 2014;39:427–440.
58. Zhao P, Xu P, Wan C, et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011(10):CD004184.
59. James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eight Joint National Committee (JNC 8) [published correction appears in JAMA. 2014;311(17):1809]. JAMA. 2014:507–520.
60. Carville S, Wonderling D, Stevens P. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ 2014 Jul 24;349.
61. Rocco MV, Sink KM, Lovato LC, et al. Effects of intensive blood pressure treatment on acute kidney injury events in the systolic blood pressure intervention trial (SPRINT). Am J Kidney Dis 2018;71:352–361.
62. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877–884.
63. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN2): multicentre, randomised controlled trial. Lancet 2005;365:939–946.
64. SPS3 Study Group; OR Benavente, CS Coffey, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–515.
65. Wright JT Jr, Bakris G, Greene T, African American Study of Kidney Disease, Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002;288:2421–2431.
66. CushmanWC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.
67. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018;72:e53–e90.
68. Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis 2021;77:110–121.
69. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393–1401.
70. de Leeuw PW, Bisognano JD, Bakris GL, et al. Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up. Hypertension 2017;69:836–843.
71. Spiering W, Williams B, Van der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017;390:2655–2661.
72. Stergiou GS, Boubouchairopoulou N, Kollias A. Accuracy of automated blood pressure measurement in children: evidence, issues, and perspectives. Hypertension 2017;69:1000–1006.
73. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension 2014;63:1116–1135.
74. Wühl E, Trivelli A, Picca S, et al, ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361: 1639–1650.
75. Lu Y, Chen R, Cai J, et al. The management of hypertension in women planning for pregnancy. Br Med Bull 2018;128:75–84.
76. Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis 2013;20:229–239.
77. Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 2015;26:1248–1260.
78. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004;43:1071–1081.
